source
- AstraZeneca's breast cancer drug camizestrant fails pivotal first-line trialAstraZeneca announced that its investigational breast cancer drug camizestrant did not meet primary endpoints in a pivotal Phase 3 trial evaluating it as a first-line treatment for advanced disease…
- FDA appoints new oncology chief, pledges ongoing innovation; approves treatments for two rare genetic disordersThe Food and Drug Administration has announced a new leader for its Oncology Center of Excellence. The appointee emphasized a continued focus on innovative cancer therapies and collaborative resear…